Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). Fragile X syndrome ...
Higher pulmonary arterial pressure in pregnant women with PH was linked to longer hospitalizations, and ICU admission, in a long-term study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback